Table of Contents Author Guidelines Submit a Manuscript
Anemia
Volume 2012 (2012), Article ID 428137, 13 pages
http://dx.doi.org/10.1155/2012/428137
Research Article

FK228 Analogues Induce Fetal Hemoglobin in Human Erythroid Progenitors

1Department of Pediatrics, Georgia Health Sciences University, Augusta, GA 30912, USA
2Department of Chemistry, University of Texas at Dallas, Richardson, TX 75083, USA
3Department of Pharmacological and Toxicological Chemistry, University of Naples Federico II, 80100 Naples, Italy
4Department of Molecular and Cell Biology, University of Texas at Dallas, TX 75080, USA
5Department of Developmental Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA

Received 16 December 2011; Accepted 7 March 2012

Academic Editor: Solomon F. Ofori-Acquah

Copyright © 2012 Levi Makala et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Papayannopoulou, A. Torrealba De Ron, and R. Veith, “Arabinosylcytosine induces fetal hemoglobin in baboons by perturbing erythroid cell differentiation kinetics,” Science, vol. 224, no. 4649, pp. 617–619, 1984. View at Google Scholar · View at Scopus
  2. D. P. Liu, C. C. Liang, Z. H. Ao et al., “Treatment of severe β-thalassemia (patients) with myleran,” American Journal of Hematology, vol. 33, no. 1, pp. 50–55, 1990. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Veith, T. Papayannopoulou, S. Kurachi, and G. Stamatoyannopoulos, “Treatment of baboon with vinblastine: insights into the mechanisms of pharmacologic stimulation of hb f in the adult,” Blood, vol. 66, no. 2, pp. 456–459, 1985. View at Google Scholar · View at Scopus
  4. R. Galanello, G. Stamatoyannopoulos, and Papayannopoulou Th., “Mechanism of hb f stimulation by s-stage compounds. in vitro studies with bone marrow cells exposed to 5-azacytidine, ara-c, or hydroxyurea,” Journal of Clinical Investigation, vol. 81, no. 4, pp. 1209–1216, 1988. View at Google Scholar · View at Scopus
  5. N. L. Letvin, D. C. Linch, and G. P. Beardsley, “Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea,” New England Journal of Medicine, vol. 310, no. 14, pp. 869–873, 1984. View at Google Scholar · View at Scopus
  6. M. H. Steinberg, F. Barton, O. Castro et al., “Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment,” Journal of the American Medical Association, vol. 289, no. 13, pp. 1645–1651, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Charache, M. L. Terrin, R. D. Moore et al., “Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia,” The New England Journal of Medicine, vol. 332, pp. 1317–1322, 1995. View at Google Scholar
  8. M. H. Steinberg, Z. H. Lu, F. B. Barton, M. L. Terrin, S. Charache, and G. J. Dover, “Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea,” Blood, vol. 89, no. 3, pp. 1078–1088, 1997. View at Google Scholar · View at Scopus
  9. X. De La Cruz, S. Lois, S. Sánchez-Molina, and M. A. Martínez-Balbás, “Do protein motifs read the histone code?” Bioessays, vol. 27, no. 2, pp. 164–175, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. P. A. Marks and X. Jiang, “Histone deacetylase inhibitors in programmed cell death and cancer therapy,” Cell Cycle, vol. 4, no. 4, pp. 549–551, 2005. View at Google Scholar · View at Scopus
  11. C. Monneret, “Histone deacetylase inhibitors,” European Journal of Medicinal Chemistry, vol. 40, no. 1, pp. 1–13, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. K. N. Prasad, “Butyric acid: a small fatty acid with diverse biological functions,” Life Sciences, vol. 27, no. 15, pp. 1351–1358, 1980. View at Publisher · View at Google Scholar · View at Scopus
  13. A. E. Smith, P. J. Hurd, A. J. Bannister, T. Kouzarides, and K. G. Ford, “Heritable gene repression through the action of a directed dna methyltransferase at a chromosomal locus,” Journal of Biological Chemistry, vol. 283, no. 15, pp. 9878–9885, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. S. D. Gore and M. A. Carducci, “Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors,” Expert Opinion on Investigational Drugs, vol. 9, no. 12, pp. 2923–2934, 2000. View at Google Scholar · View at Scopus
  15. T. Yamashita, H. Wakao, A. Miyajima, and S. Asano, “Differentiation inducers modulate cytokine signaling pathways in a murine erythroleukemia cell line,” Cancer Research, vol. 58, no. 3, pp. 556–561, 1998. View at Google Scholar · View at Scopus
  16. O. Witt, K. Sand, and A. Pekrun, “Butyrate-induced erythroid differentiation of human k562 leukemia cells involves inhibition of erk and activation of p38 map kinase pathways,” Blood, vol. 95, no. 7, pp. 2391–2396, 2000. View at Google Scholar · View at Scopus
  17. B. S. Pace, X. H. Qian, J. Sangerman et al., “P38 map kinase activation mediates γ-globin gene induction in erythroid progenitors,” Experimental Hematology, vol. 31, no. 11, pp. 1089–1096, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Torkelson, B. White, D. V. Faller, K. Phipps, C. Pantazis, and S. P. Perrine, “Erythroid progenitor proliferation is stimulated by phenoxyacetic and phenylalkyl acids,” Blood Cells, Molecules, and Diseases, vol. 22, no. 2, pp. 150–158, 1996. View at Publisher · View at Google Scholar · View at Scopus
  19. G. J. Dover, S. Brusilow, and S. Charache, “Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate,” Blood, vol. 84, no. 1, pp. 339–343, 1994. View at Google Scholar · View at Scopus
  20. E. Liakopoulou, C. A. Blau, Q. Li et al., “Stimulation of fetal hemoglobin production by short chain fatty acids,” Blood, vol. 86, no. 8, pp. 3227–3235, 1995. View at Google Scholar · View at Scopus
  21. N. Tsuji, M. Kobayashi, and K. Nagashima, “A new antifungal antibiotic, trichostatin,” Journal of Antibiotics, vol. 29, no. 1, pp. 1–6, 1976. View at Google Scholar · View at Scopus
  22. M. Yoshida, M. Kijima, M. Akita, and T. Beppu, “Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin a,” Journal of Biological Chemistry, vol. 265, no. 28, pp. 17174–17179, 1990. View at Google Scholar · View at Scopus
  23. M. S. Finnin, J. R. Donigian, A. Cohen et al., “Structures of a histone deacetylase homologue bound to the tsa and saha inhibitors,” Nature, vol. 401, no. 6749, pp. 188–193, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. V. M. Richon, S. Emiliani, E. Verdin et al., “A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 6, pp. 3003–3007, 1998. View at Publisher · View at Google Scholar · View at Scopus
  25. L. M. Butler, D. B. Agus, H. I. Scher et al., “Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo,” Cancer Research, vol. 60, no. 18, pp. 5165–5170, 2000. View at Google Scholar · View at Scopus
  26. P. A. Marks, V. M. Richon, R. Breslow, and R. A. Rifkind, “Histone deacetylase inhibitors as new cancer drugs,” Current Opinion in Oncology, vol. 13, no. 6, pp. 477–483, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Ueda, H. Nakajima, Y. Hori et al., “Fr901228, a novel antitumor bicyclic depsipeptide produced by chromobacterium violaceum no. 968. i. taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity,” Journal of Antibiotics, vol. 47, no. 3, pp. 301–310, 1994. View at Google Scholar · View at Scopus
  28. J. Johnson, R. Hunter, R. McElveen, X. H. Qian, B. S. Baliga, and B. S. Pace, “Fetal hemoglobin induction by the histone deacetylase inhibitor, scriptaid,” Cellular and Molecular Biology, vol. 51, no. 2, pp. 229–238, 2005. View at Google Scholar · View at Scopus
  29. R. Furumai, A. Matsuyama, N. Kobashi et al., “Fk228 (depsipeptide) as a natural prodrug that inhibits class i histone deacetylases,” Cancer Research, vol. 62, no. 17, pp. 4916–4921, 2002. View at Google Scholar · View at Scopus
  30. J. J. Xiao, J. Byrd, G. Marcucci, M. Grever, and K. K. Chan, “Identification of thiols and glutathione conjugates of depsipeptide fk228 (fr901228), a novel histone protein deacetylase inhibitor, in the blood,” Rapid Communications in Mass Spectrometry, vol. 17, no. 8, pp. 757–766, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Kosugi, M. Ito, Y. Yamamoto et al., “In vivo effects of a histone deacetylase inhibitor, fk228, on human acute promyelocytic leukemia in nod/shi-scid/scid mice,” Japanese Journal of Cancer Research, vol. 92, no. 5, pp. 529–536, 2001. View at Google Scholar · View at Scopus
  32. K. A. Fecteau, M. E. I. Jianxun, and H. C. Wang, “Differential modulation of signaling pathways and apoptosis of ras-transformed 10t1/2 cells by the depsipeptide fr901228,” Journal of Pharmacology and Experimental Therapeutics, vol. 300, no. 3, pp. 890–899, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Cao and G. Stamatoyannopoulos, “Histone deacetylase inhibitor fk228 is a potent inducer of human fetal hemoglobin,” American Journal of Hematology, vol. 81, no. 12, pp. 981–983, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. K. W. Li, J. Wu, W. Xing, and J. A. Simon, “Total synthesis of the antitumor depsipeptide fr-901,228,” Journal of the American Chemical Society, vol. 118, no. 30, pp. 7237–7238, 1996. View at Publisher · View at Google Scholar · View at Scopus
  35. T. J. Greshock, D. M. Johns, Y. Noguchi, and R. M. Williams, “Improved total synthesis of the potent hdac inhibitor FK228 (FK-901228),” Organic Letters, vol. 10, no. 4, pp. 613–616, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. A. A. Bowers, T. J. Greshook, N. West et al., “Synthesis and conformation-activity relationships of the peptide isosteres of fk228 and largazole,” Journal of the American Chemical Society, vol. 131, no. 8, pp. 2900–2905, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Di Maro, R. C. Pong, J. T. Hsieh, and J. M. Ahn, “Efficient solid-phase synthesis of fk228 analogues as potent antitumoral agents,” Journal of Medicinal Chemistry, vol. 51, no. 21, pp. 6639–6641, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. K. J. Jensen, J. Alsina, M. F. Songster, J. Vágner, F. Albericio, and G. Barany, “Backbone amide linker (BAL) strategy for solid-phase synthesis of c-terminal-modified and cyclic peptides,” Journal of the American Chemical Society, vol. 120, no. 22, pp. 5441–5452, 1998. View at Publisher · View at Google Scholar · View at Scopus
  39. E. Skarpidi, G. Vassilopoulos, Q. Li, and G. Stamatoyannopoulos, “Novel in vitro assay for the detection of pharmacologic inducers of fetal hemoglobin,” Blood, vol. 96, no. 1, pp. 321–326, 2000. View at Google Scholar · View at Scopus
  40. C. Y. Gui and A. Dean, “Acetylation of a specific promoter nucleosome accompanies activation of the ε-globin gene by β-globin locus control region HS2,” Molecular and Cellular Biology, vol. 21, no. 4, pp. 1155–1163, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. E. Fibach, L. P. Burke, A. N. Schechter, C. T. Noguchi, and G. P. Rodgers, “Hydroxyurea increases fetal hemoglobin in cultured erythroid cells derived from normal individuals and patients with sickle cell anemia or β- thalassemia,” Blood, vol. 81, no. 6, pp. 1630–1635, 1993. View at Google Scholar · View at Scopus
  42. J. Sangerman, S. L. Moo, X. Yao et al., “Mechanism for fetal hemoglobin induction by histone deacetylase inhibitors involves γ-globin activation by creb1 and atf-2,” Blood, vol. 108, no. 10, pp. 3590–3599, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. T. Fukuda, K. Kishi, Y. Ohnishi, and A. Shibata, “Bipotential cell differentiation of ku-812: evidence of a hybrid cell line that differentiates into basophils and macrophage-like cells,” Blood, vol. 70, no. 3, pp. 612–619, 1987. View at Google Scholar · View at Scopus
  44. K. Kishi, “A new leukemia cell line with Philadelphia chromosome characterized as basophil precursors,” Leukemia Research, vol. 9, no. 3, pp. 381–390, 1985. View at Google Scholar · View at Scopus
  45. M. Yamashita, A. Ichikawa, Y. Katakura et al., “Induction of basophilic and eosinophilic differentiation in the human leukemic cell line ku812,” Cytotechnology, vol. 36, no. 1–3, pp. 179–186, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Nakazawa, M. T. Mitjavila, N. Debili et al., “Ku 812: a pluripotent human cell line with spontaneous erythroid terminal maturation,” Blood, vol. 73, no. 7, pp. 2003–2013, 1989. View at Google Scholar · View at Scopus
  47. S. Zein, W. Li, V. Ramakrishnan et al., “Identification of fetal hemoglobin-inducing agents using the human leukemia ku812 cell line,” Experimental Biology and Medicine, vol. 235, no. 11, pp. 1385–1394, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. D. G. Nathan and R. B. Gunn, “Thalassemia: the consequences of unbalanced hemoglobin synthesis,” the American Journal of Medicine, vol. 41, no. 5, pp. 815–830, 1966. View at Google Scholar · View at Scopus
  49. M. Bhatia and M. C. Walters, “Hematopoietic cell transplantation for thalassemia and sickle cell disease: past, present and future,” Bone Marrow Transplantation, vol. 41, no. 2, pp. 109–117, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. C. E. Dunbar, “The yin and yang of stem cell gene therapy: insights into hematopoiesis, leukemogenesis, and gene therapy safety,” Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, pp. 460–465, 2007. View at Google Scholar · View at Scopus
  51. M. H. Steinberg, Z. H. Lu, F. B. Barton, M. L. Terrin, S. Charache, and G. J. Dover, “Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea,” Blood, vol. 89, no. 3, pp. 1078–1088, 1997. View at Google Scholar · View at Scopus
  52. H. Fathallah, M. Sutton, and G. F. Atweh, “Pharmacological induction of fetal hemoglobin: why haven't we been more successful in thalassemia?” Annals of the New York Academy of Sciences, vol. 1054, pp. 228–237, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. S. C. Davies and A. Gilmore, “The role of hydroxyurea in the management of sickle cell disease,” Blood Reviews, vol. 17, no. 2, pp. 99–109, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. G. F. Atweh, M. Sutton, I. Nassif et al., “Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease,” Blood, vol. 93, no. 6, pp. 1790–1797, 1999. View at Google Scholar · View at Scopus
  55. Y. Saunthararajah, R. Molokie, S. Saraf et al., “Clinical effectiveness of decitabine in severe sickle cell disease,” British Journal of Haematology, vol. 141, no. 1, pp. 126–129, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. R. Mabaera, R. J. West, S. J. Conine et al., “A cell stress signaling model of fetal hemoglobin induction: what doesn't kill red blood cells may make them stronger,” Experimental Hematology, vol. 36, no. 9, pp. 1057–1072, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. P. Constantoulakis, G. Knitter, and G. Stamatoyannopoulos, “On the induction of fetal hemoglobin by butyrates: in vivo and in vitro studies with sodium butyrate and comparison of combination treatments with 5-AZAC and ARAC,” Blood, vol. 74, no. 6, pp. 1963–1971, 1989. View at Google Scholar · View at Scopus
  58. A. Goga, J. McLaughlin, D. E. H. Afar, D. C. Saffran, and O. N. Witte, “Alternative signals to ras for hematopoietic transformation by the bcr- abl oncogene,” Cell, vol. 82, no. 6, pp. 981–988, 1995. View at Publisher · View at Google Scholar · View at Scopus
  59. R. Furumai, A. Matsuyama, N. Kobashi et al., “FK228 (depsipeptide) as a natural prodrug that inhibits class i histone deacetylases,” Cancer Research, vol. 62, no. 17, pp. 4916–4921, 2002. View at Google Scholar · View at Scopus
  60. H. Fathallah, R. S. Weinberg, Y. Galperin, M. Sutton, and G. F. Atweh, “Role of epigenetic modifications in normal globin gene regulation and butyrate-mediated induction of fetal hemoglobin,” Blood, vol. 110, no. 9, pp. 3391–3397, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. R. Mankidy, D. V. Faller, R. Mabaera et al., “Short-chain fatty acids induce γ-globin gene expression by displacement of a hdac3-ncor repressor complex,” Blood, vol. 108, no. 9, pp. 3179–3186, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. J. E. Bradner, R. Mak, S. K. Tanguturi et al., “Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 28, pp. 12617–12622, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. O. Witt, K. Sand, and A. Pekrun, “Butyrate-induced erythroid differentiation of human k562 leukemia cells involves inhibition of ERK and activation of p38 map kinase pathways,” Blood, vol. 95, no. 7, pp. 2391–2396, 2000. View at Google Scholar · View at Scopus
  64. O. Witt, S. Mönkemeyer, K. Kanbach, and A. Pekrun, “Induction of fetal hemoglobin synthesis by valproate: modulation of mapkinase pathways,” American Journal of Hematology, vol. 71, no. 1, pp. 45–46, 2002. View at Publisher · View at Google Scholar · View at Scopus